KPC Pharmaceuticals

KPC Pharmaceuticals EBIT per Employee

The EBIT per Employee of KPC Pharmaceuticals (600422.SS) as of Nov 4, 2026 is 88,981.17 CNY. In the previous year, EBIT per Employee was 176,694.71 CNY — a change of -49.64% (lower).

EBIT per Employee

88,981.17CNY

YoY

-49.64%

Last updated:

EBIT per Employee of KPC Pharmaceuticals is 2025 88,981.17 CNY. EBIT per Employee of KPC Pharmaceuticals was 2024 176,694.71 CNY. It decreases by -49.64% lower compared to the previous year.

The KPC Pharmaceuticals EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
78,882.72 CNY
Jan 1, 2019
108,558.12 CNY
Jan 1, 2020
101,621.60 CNY
Jan 1, 2021
119,136.97 CNY
Jan 1, 2022
93,413.74 CNY
Jan 1, 2023
148,378.37 CNY
Jan 1, 2024
176,694.71 CNY
Jan 1, 2025
88,981.17 CNY
The KPC Pharmaceuticals EBIT per Employee history
YEAREBIT per EmployeeYoY
88,981.17CNY-49.64%
176,694.71CNY+19.08%
148,378.37CNY+58.84%
93,413.74CNY-21.59%
119,136.97CNY+17.24%
101,621.60CNY-6.39%
108,558.12CNY+37.62%
78,882.72CNY+1.91%
77,401.59CNY-7.27%
83,471.12CNY-4.55%
87,451.83CNY+39.87%
62,524.07CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KPC Pharmaceuticals Stock analysis

What does KPC Pharmaceuticals do? KPC Pharmaceuticals, Inc. generates revenue through the research, development, manufacturing, and international marketing of its diverse drug portfolio. The company sells natural herbal medicines, traditional Chinese medicines, and chemical synthetic drugs, including central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines, and anti-inflammatory drugs. Its main customers are healthcare providers, hospitals, and pharmaceutical distributors globally. The firm also produces health products and offers medical services as additional revenue streams. The company's product segments are defined by therapeutic categories such as central nervous system treatments, cardiovascular care, and anti-inflammatory solutions. These products target both domestic and international markets, with a focus on traditional Chinese medicine and natural herbal formulations. Sales are driven by wholesale distribution networks and direct commercial partnerships in the pharmaceutical industry. KPC Pharmaceuticals' revenue model combines product sales from its core drug lines with supplementary health product offerings and medical service provision. The business leverages its manufacturing capabilities in Kunming, Yunnan to serve global markets, with a strong emphasis on traditional Chinese medicine and natural herbal medicine segments. The firm's international marketing efforts support its presence in multiple regions. KPC Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KPC Pharmaceuticals stock

EBIT per Employee of KPC Pharmaceuticals is 88,981.17 CNY in 2025.

EBIT per Employee of KPC Pharmaceuticals changed from 176,694.71 CNY to 88,981.17 CNY, representing a -49.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee KPC Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's KPC Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — KPC Pharmaceuticals

All Key Metrics — KPC Pharmaceuticals